OCUL logo

OCUL
Ocular Therapeutix Inc

12,008
Mkt Cap
$2B
Volume
603,309.00
52W High
$16.44
52W Low
$6.23
PE Ratio
-6.29
OCUL Fundamentals
Price
$9.22
Prev Close
$9.15
Open
$9.19
50D MA
$8.84
Beta
1.49
Avg. Volume
3.22M
EPS (Annual)
-$1.42
P/B
3.44
Rev/Employee
$159,849.23
$1,613.02
Loading...
Loading...
News
all
press releases
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
Key PointsAcuta Capital Partners reduced its Ocular Therapeutix holding by 460,887 shares...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
What This Fund's $14 Million Ocular Therapeutix Exit Could Signal for Investors
Key PointsSaturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million...
Nasdaq News: Markets
News Placeholder
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also decline in pre-market trading.read more...
Benzinga
News Placeholder
Ocular Therapeutix (NASDAQ:OCUL) Receives "Outperform" Rating from Royal Bank Of Canada
Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $30.00 target price on shares of Ocular Therapeutix in a report on Wednesday...
MarketBeat
News Placeholder
Ocular Therapeutix Q1 Earnings Call Highlights
Ocular Therapeutix (NASDAQ:OCUL) management used its first-quarter 2026 earnings call to highlight clinical and regulatory progress for AXPAXLI, the company's investigational therapy for wet...
MarketBeat
News Placeholder
Ocular Therapeutix (NASDAQ:OCUL) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS
Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The firm had revenue of $10.79 million for the quarter...
MarketBeat
News Placeholder
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -29.46% and -15.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Ocular Therapeutix (NASDAQ:OCUL) Share Price Crosses Above 50 Day Moving Average - Here's What Happened
Ocular Therapeutix (NASDAQ:OCUL) Stock Price Crosses Above Fifty Day Moving Average - Here's What Happened...
MarketBeat
News Placeholder
Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data
Ocular Therapeutix (NASDAQ:OCUL) Executive Chairman, President, and CEO Dr. Pravin Dugel said the company is engaged in formal discussions with the U.S. Food and Drug Administration as it works...
MarketBeat
News Placeholder
Ocular Therapeutix, Inc. $OCUL Stock Position Lessened by Deltec Asset Management LLC
Deltec Asset Management LLC cut its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 9.9% during the fourth quarter, according to the company in its most recent Form 13F...
MarketBeat
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available